Lung cancer today is treated by its biology, not just its size.
Two people with the same stage can need completely different medicines. Knowing your cell type and biomarker results is the first step. Here is what they mean, and how we support you alongside your oncology team.
READING YOUR REPORT
Three results that shape the plan
What kind of lung cancer is it?
The biopsy tells your doctors which cells the cancer came from. That decides which tests come next and which treatments are on the table.
| TYPE | WHAT IT MEANS | TREATMENTS USUALLY DISCUSSED |
|---|---|---|
| Adenocarcinomanon-small cell | The most common type, including in people who have never smoked. Often carries a targetable gene change, especially EGFR in Asian patients. | Targeted tablets if a driver mutation is found; otherwise immunotherapy and/or chemotherapy |
| Squamous cellnon-small cell | Usually starts in the larger central airways; closely linked to smoking. | Immunotherapy and chemotherapy; targetable mutations are less common |
| Small cell | Fast-growing and quick to spread; around 1 in 8 lung cancers. | Chemotherapy with immunotherapy; radiotherapy for limited-stage disease |
OTHER WORDS YOU MAY SEE
Driver mutation
A gene change fuelling growth — EGFR, ALK, ROS1, KRAS and others.
PD-L1
A protein level that helps predict benefit from immunotherapy.
Limited / extensive
The simpler staging often used for small cell lung cancer.
Liquid biopsy
A blood test that can detect tumour DNA and gene changes.
How far has it spread?
Non-small cell lung cancer is staged 0 to IV. Stage tells your team whether the goal is cure or long-term control — the biomarkers then decide how.
0
Abnormal cells in the airway lining only.
I
Small tumour in the lung, no node spread.
II
Larger, or in nodes on the same side of the lung.
III
In nodes in the centre of the chest or beyond.
IV
In the other lung, the chest lining, or organs such as brain, bone or liver.
The standard treatment pathway
Most plans mix local and whole-body treatment. Biomarker results should be back before systemic treatment starts.
TREATS THE AREA
Local treatment
Surgery — removing part or all of a lobe for early-stage disease.
Radiotherapy — including highly focused stereotactic treatment when surgery isn't suitable.
Airway procedures — laser or light-activated treatment to open a blocked airway.
TREATS THE WHOLE BODY
Systemic treatment
Targeted therapy — daily tablets matched to EGFR, ALK, ROS1 and other gene changes.
Immunotherapy — checkpoint inhibitors, alone or with chemotherapy.
Chemotherapy — before or after surgery, with radiotherapy, or for advanced disease.
Where CELLAAX fits in
We do not replace your oncologist. We review your case, share findings with your treating team, and help you weigh supportive options.
Review
A doctor reads your reports, scans and treatment history.
Coordinate
With your consent, we write to your oncologist before anything is added.
Support
A written supportive-care plan that fits around your main treatment.
Built on our 7 principles
Every plan draws on all seven principles at once, tuned to your diagnosis. Your doctor selects and sequences the therapies, and agrees them with your oncologist before anything starts.
Non-toxic therapies
Precision Molecular Approach · Thermal Energy Therapies
Immunomodulation
Bio-Immunotherapy
Full spectrum nutrition
Biological Therapies · Metabolic Therapies · Therapeutic Nutrition
Detoxification
Detoxification Therapies
Oxygenation
Oxygen Therapies
Restore the microbiome
Anti-Microbial Protocols
Noticed a change?
Most lung cancer changes are not cancer, but none should be ignored. See a doctor promptly — even if your last mammogram was clear.
- Persistent cough that does not go away or gets worse
- Coughing up blood or rust-colored sputum
- Shortness of breath, wheezing or hoarseness
- Chest pain that worsens with deep breathing, coughing or laughing
Take our questionnaire to determine your next step.
Common questions
Can non-smokers get lung cancer?
Yes. Up to 20% of lung cancers occur in people who never smoked, often driven by specific genetic mutations such as EGFR or ALK.
What is biomarker testing and why is it important?
Biomarker testing checks your tumor tissue or blood for gene changes. It helps find targeted therapies that work specifically against those changes.
How can integrative care help during lung cancer treatment?
Our supportive care helps manage shortness of breath, fatigue, appetite loss and side effects while protecting your overall strength.
Do I need a doctor's referral to consult CELLAAX?
No referral is needed. You can reach out directly to book a consultation with our integrative medical team.

Ready to discuss your lung cancer diagnosis?
Book a free consultation. Our doctors will review your reports and explain how integrative care fits into your journey.
